Key result
Class III obesity is linked to ~39% lower long-term mortality in non-ischemic HFpEF only.
Why the study?
Whether heart failure etiology modifies the obesity paradox in patients with HFpEF remains controversial.
Does obesity reduce all-cause death risk differently in HFpEF patients with ischemic versus non-ischemic etiology?
Observational (n=3,360)
Does obesity reduce all-cause death risk differently in HFpEF patients with ischemic versus non-ischemic etiology?
The 'obesity paradox' in HFpEF is modified by heart failure etiology, persisting long-term in non-ischemic patients but disappearing in those with ischemic etiology.
Answers are grounded in this paper and cite their sources.
Etiology may modify long-term obesity paradox in HFpEF; leaves open whether ischemic patients need distinct weight strategies.
Background Obesity could paradoxically improve prognosis in patients with heart failure (HF), termed the “obesity paradox.” Whether HF etiology could modify the “obesity paradox” is still controversial. In the present study, we aimed to assess the relationship between obesity and death in patients with heart failure with preserved ejection fraction (HFpEF) with non-ischemic versus ischemic etiologies. Methods We analyzed 3,360 HFpEF patients from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial. Cox regression models were used to assess the association of obesity assessed by body mass index (BMI) with short-term and long-term death risk. Results Overweight and obesity were associated with a lower risk of long-term all-cause death in patients with non-ischemic HFpEF, even in those with class III obesity (adjusted HR: 0.61, 95% CI 0.38–0.97). However, in the ischemic subgroup, as obesity advanced, this paradoxical relationship was gradually attenuated and disappeared in class III obesity (adjusted HR: 0.93, 95% CI 0.56–1.57). Restricted cubic spline analyses confirmed the differential relationship of baseline BMI with risk of long-term death with a BMI higher than 30 kg/m2 in non-ischemic versus ischemic HFpEF. In the short-term follow-up, the beneficial effects of overweight and obesity on survival were consistently observed in all the BMI categories, with the nadirs of all-cause death risk at class III obesity category both in non-ischemic and ischemic subgroups. Conclusion “Obesity paradox” was evident both in non-ischemic and ischemic HFpEF during short-term follow-up, even in those with class III obesity. However, the beneficial effect of class III obesity disappeared during long-term follow-up in ischemic HFpEF. Clinical Trial Registration [ https://clinicaltrials.gov ], identifier [NCT00094302].
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2022) conducted an observational in Heart failure with preserved ejection fraction (HFpEF) (n=3,360). Obesity (assessed by body mass index) vs. Lower BMI categories was evaluated on Long-term all-cause death in non-ischemic HFpEF with class III obesity (HR 0.61, 95% CI 0.38-0.97). Class III obesity was associated with a lower risk of long-term all-cause death in non-ischemic HFpEF, but this benefit disappeared in ischemic HFpEF.
Synapse has enriched 10 related papers. Consider them for comparative context: